EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis

Sponsor
Hoffmann-La Roche
Study ID
NCT02648035
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tocilizumab — BIOLOGICAL
    Subcutaneous Tocilizumab according to approved label.

Study Details

The purpose of this study is to evaluate the percentage of participants treated with subcutaneous (SC) Tocilizumab who are still on treatment after 52 weeks and the factors that play a major role in continuation of treatment.

Key Dates

Start date
Sep 22, 2016
Status verified
Mar 2019
Primary completion
Dec 20, 2018
Completion
Dec 20, 2018

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Subcutaneous Tocilizumab
    Participants receiving treatment for rheumatoid arthritis (RA) with subcutaneous Tocilizumab alone or in combination with conventional disease-modifying antirheumatic drugs (DMARDs) according to approved label.

Primary Outcome Measure

Percentage of Participants Still Receiving Subcutaneous Tocilizumab Therapy at 52 Weeks of Observation [ Time Frame: At 52 weeks ]

Related Studies